Basilea Pharmaceutica AG (SWX:BSLN)

Market Cap	841.96M +44.9%
Revenue (ttm)	247.42M +4.7%
Net Income	52.38M -27.9%
EPS	4.01 -26.7%
Shares Out	12.42M
PE Ratio	16.91
Forward PE	15.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,361
Open	67.60
Previous Close	67.80
Day's Range	66.30 - 67.70
52-Week Range	44.70 - 70.50
Beta	0.43
Analysts	Buy
Price Target	107.78 (+60.15%)
Est. Earnings	Nov 18, 2026

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 200
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2025, Basilea Pharmaceutica AG's revenue was 232.38 million, an increase of 11.43% compared to the previous year's 208.54 million. Earnings were 40.24 million, a decrease of -48.14%.

Analyst Summary

According to 4 analysts, the average rating for BSLN stock is "Buy." The 12-month stock price target is CHF 107.78, which is an increase of 60.15% from the latest price.

Price Target

CHF 107.78

(60.15% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error